

MERIDIAN BIOSCIENCE INC
Form 8-K
September 23, 2010

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2010

MERIDIAN BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Ohio (State or other jurisdiction of incorporation)	0-14902 (Commission File Number)	31-0888197 (IRS Employer Identification No.)
3471 River Hills Drive, Cincinnati, Ohio (Address of principal executive offices)		45244 (Zip Code)

Registrant's telephone number, including area code (513) 271-3700

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On September 17, 2010 James A. Buzard, who is age 82 and resides in Lake Forest Illinois, informed Meridian Bioscience, Inc. Executive Chairman, William J. Motto, of his plans to retire from the Board at the end of his term in January 2011. He will not stand for re-election at the Company's 2011 Annual Meeting. A director of the Company since 1990, Dr. Buzard serves as the Chairman of the Board's Nominating and Corporate Governance Committee. The Company is grateful for Dr. Buzard's many years of dedicated service.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MERIDIAN BIOSCIENCE, INC.

Date: September 23, 2010

By: /s/ Melissa Lueke
Melissa Lueke
Executive Vice President and Chief
Financial Officer
(Principal Accounting Officer)